Abstract
Curative therapy for childhood and adolescent cancer translates to 1 in 640 young adults being a survivor of cancer. Although acute hepato-biliary toxicity occurs commonly during pediatric cancer therapy, the impact of antineoplastic therapy on long-term liver health in childhood/adolescent cancer survivors is unknown. This article reviews the medical literature on late liver dysfunction following treatment for childhood/adolescent cancer. We also outline the Children's Oncology Group (COG) guidelines for screening and follow-up of hepato-biliary sequelae. As the population of survivors grow and age, vigilance for risks to hepatic health needs to continue based on specific exposures during curative cancer therapy.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Adolescent
-
Antineoplastic Agents / adverse effects
-
Bile Duct Diseases / etiology
-
Bile Duct Diseases / prevention & control*
-
Chemical and Drug Induced Liver Injury, Chronic / etiology
-
Chemical and Drug Induced Liver Injury, Chronic / prevention & control
-
Child
-
Continuity of Patient Care*
-
Hepatitis, Viral, Human / etiology
-
Hepatitis, Viral, Human / prevention & control
-
Humans
-
Liver Diseases / etiology
-
Liver Diseases / prevention & control*
-
Mass Screening* / methods
-
Neoplasms / complications
-
Neoplasms / therapy*
-
Practice Guidelines as Topic
-
Radiotherapy / adverse effects
-
Stem Cell Transplantation / adverse effects
-
Survivors
-
Transfusion Reaction